Clinical importance of OATP1B1 and OATP1B3 in drugdrug interactions

Drug Metabolism and Pharmacokinetics

Volumn 26, Issue 3, 2011, Pages 220-227

  Shitara, Yoshihisa ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Drugdrug interactions; Hepatic transport; OATP; Pharmacokinetics; Transporters

Indexed keywords

ATORVASTATIN; BOSENTAN; CERIVASTATIN; CLARITHROMYCIN; CYCLOSPORIN A; FLUINDOSTATIN; GEMFIBROZIL; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOPINAVIR; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B1; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B3; PRAVASTATIN; REPAGLINIDE; RIFAMPICIN; RITONAVIR; ROSUVASTATIN; SIMVASTATIN; TORASEMIDE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CLINICAL PHARMACOLOGY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; GENE; GENETIC POLYMORPHISM; HUMAN; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B1 GENE; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B3 GENE; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW;

EID: 79959935821     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-10-RV-094     Document Type: Review

References (93)

1. Ito, K., Iwatsubo, T., Kanamitsu, S., Ueda, K., Suzuki, H. and Sugiyama, Y.: Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol. Rev., 50: 387-412 (1998).
2. Ohno, Y., Hisaka, A. and Suzuki, H.: General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin. Pharmacokinet., 46: 681-696 (2007).
3. Ohno, Y., Hisaka, A., Ueno, M. and Suzuki, H.: General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. Clin. Pharmacokinet., 47: 669-680 (2008).
4. Houston, J. and Galetin, A.: In vitro techniques to study drug-drug interactions of drug metabolism: Cytochrome P450. In Pang, S. K., Rodriguez, A. D. and Peter, R. M. (eds.): Enzyme-and transporterbased drug-drug interactions, New York, Springer, 2010, pp. 169-215.
5. Grover, A. and Benet, L. Z.: Transporter-based drug-drug interactions and their effect on distribution volumes. In Pang, S. K., Rodriguez, A. D. and Peter, R. M. (eds.): Enzyme-and transporter-based drug-drug interactions, New York, Springer, 2010, pp. 437-471.
6. Tanigawara, Y.: Role of P-glycoprotein in drug disposition. Ther. Drug Monit., 22: 137-140 (2000).
7. Benet, L. Z., Cummins, C. L. and Wu, C. Y.: Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr. Drug Metab., 4: 393-398 (2003).
8. Hoffmann, U. and Kroemer, H. K.: The ABC transporters MDR1 and MRP2: multiple functions in disposition of xenobiotics and drug resistance. Drug Metab. Rev., 36: 669-701 (2004).
9. Aszalos, A.: P-glycoprotein-based drug-drug interactions: preclinical methods and relevance to clinical observations. Arch. Pharm. Res., 27: 127-135 (2004).
10. Zhou, S., Lim, L. Y. and Chowbay, B.: Herbal modulation of P-glycoprotein. Drug Metab. Rev., 36: 57-104 (2004).
11. Lee, C. A., Cook, J. A., Reyner, E. L. and Smith, D. A.: P-glycoprotein-related drug interactions: clinical importance and a consideration of disease states. Expert Opin. Drug Metab. Toxicol., 6: 603-619 (2010).
12. Hagenbuch, B. and Meier, P. J.: The superfamily of organic anion transporting polypeptides. Biochim. Biophys. Acta, 1609: 1-18 (2003).
13. Hagenbuch, B. and Meier, P. J.: Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/ functional properties. Pflugers Arch., 447: 653-665 (2004).
14. Smith, N. F., Figg, W. D. and Sparreboom, A.: Role of the liverspecific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin. Drug Metab. Toxicol., 1: 429-445 (2005).
15. Giacomini, K. M. and Sugiyama, Y.: Membrane transporters and drug response. In Brunton L. L., Lazo J. S. and Parker K. L. (eds.): Goodman & Gilmanös the pharmacological basis of therapeutics, 11th edition, New York, McGraw-Hill Professional, 2005, pp. 41-70.
16. König, J., Cui, Y., Nies, A. T. and Keppler, D.: A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am. J. Physiol. Gastrointest. Liver Physiol., 278: G156-G164 (2000).
17. Hsiang, B., Zhu, Y., Wang, Z., Wu, Y., Sasseville, V., Yang, W. P. and Kirchgessner, T. G.: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J. Biol. Chem., 274: 37161-37168 (1999).
18. Fujiwara, K., Adachi, H., Nishio, T., Unno, M., Tokui, T., Okabe, M., Onogawa, T., Suzuki, T., Asano, N., Tanemoto, M., Seki, M., Shiiba, K., Suzuki, M., Kondo, Y., Nunoki, K., Shimosegawa, T., Iinuma, K., Ito, S., Matsuno, S. and Abe, T.: Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology, 142: 2005-2012 (2001).
19. Mikkaichi, T., Suzuki, T., Tanemoto, M., Ito, S. and Abe, T.: The organic anion transporter (OATP) family. Drug Metab. Pharmacokinet., 19: 171-179 (2004).
20. König, J., Cui, Y., Nies, A. T. and Keppler, D.: Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J. Biol. Chem., 275: 23161-23168 (2000).
21. Abe, T., Unno, M., Onogawa, T., Tokui, T., Kondo, T. N., Nakagomi, R., Adachi, H., Fujiwara, K., Okabe, M., Suzuki, T., Nunoki, K., Sato, E., Kakyo, M., Nishio, T., Sugita, J., Asano, N., Tanemoto, M., Seki, M., Date, F., Ono, K., Kondo, Y., Shiiba, K., Suzuki, M., Ohtani, H., Shimosegawa, T., Iinuma, K., Nagura, H., Ito, S. and Matsuno, S.: LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology, 120: 1689-1699 (2001).
22. Muto, M., Onogawa, T., Suzuki, T., Ishida, T., Rikiyama, T., Katayose, Y., Ohuchi, N., Sasano, H., Abe, T. and Unno, M.: Human liver-specific organic anion transporter-2 is a potent prognostic factor for human breast carcinoma. Cancer Sci., 98: 1570-1576 (2007).
23. Li, L., Meier, P. J. and Ballatori, N.: Oatp2 mediates bidirectional organic solute transport: a role for intracellular glutathione. Mol. Pharmacol., 58: 335-340 (2000).
24. Mahagita, C., Grassl, S. M., Piyachaturawat, P. and Ballatori, N.: Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport. Am. J. Physiol. Gastrointest. Liver Physiol., 293: G271-G278 (2007).
25. Yamazaki, M., Suzuki, H. and Sugiyama, Y.: Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm. Res., 13: 497-513 (1996).
26. Shitara, Y., Horie, T. and Sugiyama, Y.: Transporters as a determinant of drug clearance and tissue distribution. Eur. J. Pharm. Sci., 27: 425-446 (2006).
27. Mück, W., Mai, I., Fritsche, L., Ochmann, K., Rohde, G., Unger, S., Johne, A., Bauer, S., Budde, K., Roots, I., Neumayer, H. H. and Kuhlmann, J.: Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin. Pharmacol. Ther., 65: 251-261 (1999).
28. Shitara, Y., Hirano, M., Adachi, Y., Itoh, T., Sato, H. and Sugiyama, Y.: In vitro and in vivo correlation of the inhibitory effect of cyclosporin A on the transporter-mediated hepatic uptake of cerivastatin in rats. Drug Metab. Dispos., 32: 1468-1475 (2004).
29. Mück, W.: Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions. Drugs, 56 Suppl. 1: 15-23, discussion 33 (1998).
30. Zhang, L., Zhang, Y. and Huang, S. M.: Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions. Mol. Pharm., 6: 1766-1774 (2009).
31. Giacomini, K. M., Huang, S. M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L., Chu, X., Dahlin, A., Evers, R., Fischer, V., Hillgren, K. M., Hoffmaster, K. A., Ishikawa, T., Keppler, D., Kim, R. B., Lee, C. A., Niemi, M., Polli, J. W., Sugiyama, Y., Swaan, P. W., Ware, J. A., Wright, S. H., Yee, S. W., Zamek-Gliszczynski, M. J. and Zhang, L.: Membrane transporters in drug development. Nat. Rev. Drug Discov., 9: 215-236 (2010).
32. Maeda, K. and Sugiyama, Y.: Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab. Pharmacokinet., 23: 223-235 (2008).
33. Ieiri, I., Higuchi, S. and Sugiyama, Y.: Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin. Drug Metab. Toxicol., 5: 703-729 (2009).
34. Shitara, Y. and Sugiyama, Y.: Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol. Ther., 112: 71-105 (2006).
35. Romaine, S. P. R., Bailey, K. M., Hall, A. S. and Balmforth, A. J.: The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J., 10: 1-11 (2010).
36. The SEARCH Collaborative Group, Link, E., Parish, S., Armitage, J., Bowman, L., Heath, S., Matsuda, F., Gut, I., Lathrop, M. and Collins, R.: SLCO1B1 variants and statin-induced myopathy-a genomewide study. N. Engl. J. Med., 359: 789-799 (2008).
37. Pasanen, M. K., Neuvonen, M., Neuvonen, P. J. and Niemi, M.: SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics, 16: 873-879 (2006).
38. Chen, C., Mireles, R. J., Campbell, S. D., Lin, J., Mills, J. B., Xu, J. J. and Smolarek, T. A.: Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab. Dispos., 33: 537-546 (2005).
39. Hartkoorn, R. C., Kwan, W. S., Shallcross, V., Chaikan, A., Liptrott, N., Egan, D., Sora, E. S., James, C. E., Gibbons, S., Bray, P. G., Back, D. J., Khoo, S. H. and Owen, A.: HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet. Genomics, 20: 112-120 (2010).
40. Werner, U., Werner, D., Heinbuchner, S., Graf, B., Ince, H., Kische, S., Thurmann, P., Konig, J., Fromm, M. F. and Zolk, O.: Gender is an important determinant of the disposition of the loop diuretic torasemide. J. Clin. Pharmacol., 50: 160-168 (2010).
41. Picard, N., Yee, S. W., Woillard, J. B., Lebranchu, Y., Le Meur, Y., Giacomini, K. M. and Marquet, P.: The role of organic aniontransporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin. Pharmacol. Ther., 87: 100-108 (2010).
42. Niemi, M., Kivisto, K. T., Hofmann, U., Schwab, M., Eichelbaum, M. and Fromm, M. F.: Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br. J. Clin. Pharmacol., 59: 602-604 (2005).
43. Bernsdorf, A., Giessmann, T., Modess, C., Wegner, D., Igelbrink, S., Hecker, U., Haenisch, S., Cascorbi, I., Terhaag, B. and Siegmund, W.: Simvastatin does not influence the intestinal Pglycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. Br. J. Clin. Pharmacol., 61: 440-450 (2006).
44. Niemi, M., Kivisto, K. T., Diczfalusy, U., Bodin, K., Bertilsson, L., Fromm, M. F. and Eichelbaum, M.: Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. Pharmacogenet. Genomics, 16: 565-568 (2006).
45. Oswald, S., Konig, J., Lutjohann, D., Giessmann, T., Kroemer, H. K., Rimmbach, C., Rosskopf, D., Fromm, M. F. and Siegmund, W.: Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1. Pharmacogenet. Genomics, 18: 559-568 (2008).
46. Shitara, Y., Itoh, T., Sato, H., Li, A. P. and Sugiyama, Y.: Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J. Pharmacol. Exp. Ther., 304: 610-616 (2003).
47. Hirano, M., Maeda, K., Shitara, Y. and Sugiyama, Y.: Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab. Dispos., 34: 1229-1236 (2006).
48. Adachi, Y., Suzuki, H. and Sugiyama, Y.: Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in situ and in vitro. Pharm. Res., 20: 1163-1169 (2003).
49. Shitara, Y., Nagamatsu, Y., Wada, S., Sugiyama, Y. and Horie, T.: Long-lasting inhibition of the transporter-mediated hepatic uptake of sulfobromophthalein by cyclosporin A in rats. Drug Metab. Dispos., 37: 1172-1178 (2009).
50. Amundsen, R., Christensen, H., Zabihyan, B. and Asberg, A.: Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin. Drug Metab. Dispos., 38: 1499-1504 (2010).
51. Shitara, Y., Hirano, M., Sato, H. and Sugiyama, Y.: Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther., 311: 228-236 (2004).
52. Yamazaki, M., Li, B., Louie, S. W., Pudvah, N. T., Stocco, R., Wong, W., Abramovitz, M., Demartis, A., Laufer, R., Hochman, J. H., Prueksaritanont, T. and Lin, J. H.: Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2-and P-glycoprotein-mediated transport. Xenobiotica, 35: 737-753 (2005).
53. Schneck, D. W., Birmingham, B. K., Zalikowski, J. A., Mitchell, P. D., Wang, Y., Martin, P. D., Lasseter, K. C., Brown, C. D., Windass, A. S. and Raza, A.: The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin. Pharmacol. Ther., 75: 455-463 (2004).
54. Nakagomi-Hagihara, R., Nakai, D., Tokui, T., Abe, T. and Ikeda, T.: Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1. Xenobiotica, 37: 474-486 (2007).
55. Hinton, L. K., Galetin, A. and Houston, J. B.: Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozildrug interactions. Pharm. Res., 25: 1063-1074 (2008).
56. Wen, X., Wang, J. S., Backman, J. T., Kivisto, K. T. and Neuvonen, P. J.: Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab. Dispos., 29: 1359-1361 (2001).
57. Wang, J. S., Neuvonen, M., Wen, X., Backman, J. T. and Neuvonen, P. J.: Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab. Dispos., 30: 1352-1356 (2002).
58. Ogilvie, B. W., Zhang, D., Li, W., Rodrigues, A. D., Gipson, A. E., Holsapple, J., Toren, P. and Parkinson, A.: Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab. Dispos., 34: 191-197 (2006).
59. Kyrklund, C., Backman, J. T., Neuvonen, M. and Neuvonen, P. J.: Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin. Pharmacol. Ther., 73: 538-544 (2003).
60. Whitfield, L. R., Porcari, A. R., Alvey, C., Abel, R., Bullen, W. and Hartman, D.: Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin. J. Clin. Pharmacol., in press.
61. Noé, J., Portmann, R., Brun, M. E. and Funk, C.: Substratedependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab. Dispos., 35: 1308-1314 (2007).
62. Lau, Y. Y., Huang, Y., Frassetto, L. and Benet, L. Z.: Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin. Pharmacol. Ther., 81: 194-204 (2007).
63. Kiser, J. J., Gerber, J. G., Predhomme, J. A., Wolfe, P., Flynn, D. M. and Hoody, D. W.: Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J. Acquir. Immune Defic. Syndr., 47: 570-578 (2008).
64. Dingemanse, J., van Giersbergen, P. L., Patat, A. and Nilsson, P. N.: Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants. Antivir. Ther., 15: 157-163 (2010).
65. Jacobson, T. A.: Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am. J. Cardiol., 94: 1140-1146 (2004).
66. Watanabe, T., Kusuhara, H., Maeda, K., Shitara, Y. and Sugiyama, Y.: Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J. Pharmacol. Exp. Ther., 328: 652-662 (2009).
67. Lennernäs, H.: Clinical pharmacokinetics of atorvastatin. Clin. Pharmacokinet., 42: 1141-1160 (2003).
68. Mück, W.: Clinical pharmacokinetics of cerivastatin. Clin. Pharmacokinet., 39: 99-116 (2000).
69. Scripture, C. D. and Pieper, J. A.: Clinical pharmacokinetics of fluvastatin. Clin. Pharmacokinet., 40: 263-281 (2001).
70. Hatanaka, T.: Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin. Pharmacokinet., 39: 397-412 (2000).
71. Martin, P. D., Warwick, M. J., Dane, A. L., Brindley, C. and Short, T.: Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin. Ther., 25: 2553-2563 (2003).
72. Hatorp, V.: Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin. Pharmacokinet., 41: 471-483 (2002).
73. Marbury, T. C., Ruckle, J. L., Hatorp, V., Andersen, M. P., Nielsen, K. K., Huang, W. C. and Strange, P.: Pharmacokinetics of repaglinide in subjects with renal impairment. Clin. Pharmacol. Ther., 67: 7-15 (2000).
74. Dingemanse, J. and van Giersbergen, P. L.: Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin. Pharmacokinet., 43: 1089-1115 (2004).
75. Pasanen, M. K., Fredrikson, H., Neuvonen, P. J. and Niemi, M.: Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther., 82: 726-733 (2007).
76. Hedman, M., Antikainen, M., Holmberg, C., Neuvonen, M., Eichelbaum, M., Kivisto, K. T., Neuvonen, P. J. and Niemi, M.: Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. Br. J. Clin. Pharmacol., 61: 706-715 (2006).
77. Igel, M., Arnold, K. A., Niemi, M., Hofmann, U., Schwab, M., Lütjohann, D., von Bergmann, K., Eichelbaum, M. and Kivistö, K. T.: Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin. Pharmacol. Ther., 79: 419-426 (2006).
78. Nishizato, Y., Ieiri, I., Suzuki, H., Kimura, M., Kawabata, K., Hirota, T., Takane, H., Irie, S., Kusuhara, H., Urasaki, Y., Urae, A., Higuchi, S., Otsubo, K. and Sugiyama, Y.: Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther., 73: 554-565 (2003).
79. Zhang, W., He, Y. J., Han, C. T., Liu, Z. Q., Li, Q., Fan, L., Tan, Z. R., Zhang, W. X., Yu, B. N., Wang, D., Hu, D. L. and Zhou, H. H.: Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. Br. J. Clin. Pharmacol., 62: 567-572 (2006).
80. Kalliokoski, A., Neuvonen, M., Neuvonen, P. J. and Niemi, M.: The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range. Br. J. Clin. Pharmacol., 66: 818-825 (2008).
81. Niemi, M., Backman, J. T., Kajosaari, L. I., Leathart, J. B., Neuvonen, M., Daly, A. K., Eichelbaum, M., Kivisto, K. T. and Neuvonen, P. J.: Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. Pharmacol. Ther., 77: 468-478 (2005).
82. Kalliokoski, A., Neuvonen, M., Neuvonen, P. J. and Niemi, M.: Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J. Clin. Pharmacol., 48: 311-321 (2008).
83. Wen, J. and Xiong, Y.: OATP1B1 388AhG polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers. J. Clin. Pharm. Ther., 35: 99-104 (2010).
84. Asberg, A., Hartmann, A., Fjeldsa, E., Bergan, S. and Holdaas, H.: Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am. J. Transplant., 1: 382-386 (2001).
85. Hermann, M., Asberg, A., Christensen, H., Holdaas, H., Hartmann, A. and Reubsaet, J. L.: Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients. Clin. Pharmacol. Ther., 76: 388-391 (2004).
86. Park, J. W., Siekmeier, R., Lattke, P., Merz, M., Mix, C., Schuler, S. and Jaross, W.: Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. J. Cardiovasc. Pharmacol. Ther., 6: 351-361 (2001).
87. Hedman, M., Neuvonen, P. J., Neuvonen, M., Holmberg, C. and Antikainen, M.: Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin. Pharmacol. Ther., 75: 101-109 (2004).
88. Simonson, S. G., Raza, A., Martin, P. D., Mitchell, P. D., Jarcho, J. A., Brown, C. D., Windass, A. S. and Schneck, D. W.: Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin. Pharmacol. Ther., 76: 167-177 (2004).
89. Kajosaari, L. I., Niemi, M., Neuvonen, M., Laitila, J., Neuvonen, P. J. and Backman, J. T.: Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin. Pharmacol. Ther., 78: 388-399 (2005).
90. Binet, I., Wallnofer, A., Weber, C., Jones, R. and Thiel, G.: Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. Kidney Int., 57: 224-231 (2000).
91. Backman, J. T., Kyrklund, C., Neuvonen, M. and Neuvonen, P. J.: Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin. Pharmacol. Ther., 72: 685-691 (2002).
92. Spence, J. D., Munoz, C. E., Hendricks, L., Latchinian, L. and Khouri, H. E.: Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am. J. Cardiol., 76: 80A-83A (1995).
93. Kalliokoski, A., Backman, J. T., Kurkinen, K. J., Neuvonen, P. J. and Niemi, M.: Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism. Clin. Pharmacol. Ther., 84: 488-496 (2008).